Plethora Solutions Holdings plc: Fortacin™ is the first EU approved prescription treatment for premature ejaculation (“PE”) that does not act on the central nervous system. The treatment is a topical spray containing low doses of lidocaine and prilocaine that take effect almost immediately upon application, giving users more control without reducing pleasure. Plethora / Regent has recently entered into a license agreement with a wholly owned subsidiay of Shanghai Fosun Pharmaceuticals for $38M upfront and royalties that range from low to high-teens after hitting certain milestones related to the PRC roll-out. Based on Fosun’s estimates Fortacin™ has the potential to help an initial target market of approximately 9 million patients in China in its first year of launch, rising to over 170 million patients by its tenth year. The rights to Fortacin™ for Europe, Turkey, Russia and certain countries of North Africa were out-licensed to Recordati and commercial sales started in middle of 2018 in Italy, Germany, France, Portugal and Spain. Recordati will roll out Fortacin™ in the UK and other European countries in 2019.
Biotech Company
Based in...
Clinical Stage
Disease Space
Men's Health, Urology
Specialty Pharmaceutical
Market Cap
Hampden House, Monument Business Park
Warpsgrove Lane
Chalgrove, Oxfordshire, OX44 7RW

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.